-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-10-06
Saito and colleagues report a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids can be propagated, cryopreserved, and converted into intestinal epithelial monolayers containing functionally relevant enterocytes for drug absorption, transporter, and metabolism studies.
-
Tamsulosin: Mechanism, Evidence, and Limits
2026-10-05
Tamsulosin is a selective α1-adrenergic receptor antagonist whose main research and clinical relevance involves lower-urinary-tract smooth muscle tone. Evidence supports context-dependent use in urological disease research, but stone passage and postoperative urinary-retention findings should not be generalized to prostate-cancer prognosis or androgen biology.
-
Metoprolol Tartrate and β1 Signaling Research
2026-10-05
A source-grounded overview of Metoprolol Tartrate as a β1-adrenergic blocking agent, with emphasis on receptor selectivity, cardiovascular research context, hematopoietic transplantation findings, evidence strength, and applicability limits.
-
Bleomycin Sulfate in DNA Damage and Fibrosis Research
2026-10-04
Bleomycin Sulfate is used both as a cytotoxic therapeutic and as a research perturbant for DNA damage and tissue injury. This overview compares supplier-described applications with findings from a 2026 macrophage-targeted STING gene-editing study, emphasizing evidence provenance, model limitations, pathway interpretation, and the boundaries between pulmonary fibrosis research and human disease.
-
GSK343 and the TERT–PRC2 Evidence Gap
2026-10-03
GSK343 is a selective EZH2 inhibitor that can help connect PRC2 chromatin regulation with TERT control. This article interprets that connection through a recent human stem-cell study while separating biochemical potency, cellular activity, and causal evidence.
-
Dual-Recombinase Tracing Finds No Mouse Neo-Oogenesis
2026-10-02
Xie, Zhou, and Zheng combined Cre-loxP and Dre-rox lineage tracing to test whether postnatal ovarian cells generate new oocytes in mice. Across physiological aging and busulfan-induced ovarian injury, the study found no labeled growing oocytes or metaphase II eggs, strengthening the evidence against in vivo postnatal neo-oogenesis under the tested conditions.
-
Stable Isotope UHPLC–MS/MS for Methylated Nucleosides
2026-10-01
The reference study develops a stable isotope-diluted UHPLC–ESI–MS/MS workflow for sensitive, quantitative analysis of methylated purine nucleosides in cellular samples. Its combination of ammonium bicarbonate-enhanced ionization, chromatographic isomer separation, and extraction cleanup improves measurement reliability for RNA modification research, metabolomics, and biomarker discovery.
-
Rucaparib (AG-014699) DNA Repair Workflows
2026-10-01
Rucaparib (AG-014699) enables controlled studies of PARP1 inhibition, persistent DNA breaks, and radiation response across repair-deficient cancer models. This practical guide connects radiosensitization assays with emerging SmD2–BRCA1/FANC splicing biology in hepatocellular carcinoma.
-
Dextromethorphan Hydrobromide: Assay Architecture
2026-09-30
Dextromethorphan hydrobromide is a versatile NMDA receptor antagonist for mechanistic neuroprotection research. This guide develops an assay-architecture framework that separates receptor effects, ion-channel modulation, and translational evidence while placing the compound in proper scientific context.
-
Busulfan Workflows for Senescence and Germ-Cell Models
2026-09-30
Busulfan enables two complementary experimental designs: controlled senescence induction in WI38 fibroblasts and targeted germ-cell injury in mouse models. This workflow guide connects DNA crosslinking, MAPK signaling, and dual-recombinase lineage tracing while emphasizing dosing discipline, assay controls, and interpretation limits.
-
Oteseconazole (VT-1161): CYP51 Antifungal Guide
2026-09-29
Oteseconazole, also called VT-1161, is a selective tetrazole CYP51 inhibitor with potent in vitro activity against multiple Candida species. Its strongest translational role is prevention of recurrent vulvovaginal candidiasis, while laboratory data support research on Candida albicans and fluconazole-resistant Candida.
-
NP-40 Lysis Buffer: Reliable Native Protein Workflows
2026-09-29
Learn how NP-40 Lysis Buffer supports reproducible protein recovery for viability, proliferation, cytotoxicity, and neuroimmune assays. This scenario-based guide explains when SKU K1127 is appropriate, how to optimize it, and how to evaluate formulation quality, workflow cost, and vendor reliability.
-
Baicalein and Selective Pathway Modulation
2026-09-28
Baicalein is a 12-lipoxygenase pathway inhibitor used to investigate arachidonic acid metabolism, inflammation, and cancer-cell responses. This article connects its pathway-focused research applications to a neurotoxicity study that illustrates why protective effects in one cell type cannot be assumed to preserve drug activity in another.
-
XPO1 Inhibition Limits Colorectal Tumorigenesis
2026-09-27
A 2024 bioRxiv preprint reports that the XPO1 inhibitor Eltanexor reduces COX-2 expression by modulating Wnt/β-catenin signaling and lowers tumor burden in Apcmin/+ mice. The findings connect nuclear export to a key colorectal cancer pathway and support further evaluation of XPO1 inhibition as a chemoprevention strategy, while remaining preclinical.
-
ICI 118,551 Hydrochloride in Stroke Research
2026-09-26
Use ICI 118,551 hydrochloride as a hypothesis-testing pharmacological probe alongside CKLF1-focused neutrophil assays—not as an established stroke treatment or a substitute for esculetin. The workflow below separates the reference study’s findings from proposed assay conditions and shows how to test for independent or interacting effects.